test

Available Trials

Colorectal Cancer

10
(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 4 - LGX818 for patients with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
A Phase II Multi-center, Randomized, Placebo-Controlled Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer
Disease/Condition: Colon
Principal Investigator: Howard Hochster
A Phase III, Double Blind, Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Disease/Condition: Colon
Principal Investigator: Sajid Khan
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Disease/Condition: Anus | Colon
Principal Investigator: Neal Fischbach
A Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors
Principal Investigator: Melinda Irwin
Phase 2 study of PF-05212384 plus irinotecan vs. cetuximab plus irinotecan in KRAS & NRAS wt mCLC
Disease/Condition: Anus | Colon
Principal Investigator: Howard Hochster
Phase 3 Study of Adjuvant Regorafenib vs. Placebo for Patients with Stage 4 colorectal cancer
Disease/Condition: Colon | Liver | Rectum
Principal Investigator: Howard Hochster
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
Phase Ib/II study of LGX818 and cetuximab or LGX818, BYL719 and cetuximab in BRAF mutant mCRC
Disease/Condition: Colon | Rectum
Principal Investigator: Howard Hochster
Pilot Trial of KD018 with Neo-Adj Concurrent Chemo-RT in PTs with Rectal CA
Disease/Condition: Rectum
Principal Investigator: Susan Higgins
STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regiments (Concurrent and Sequential) vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer
Disease/Condition: Colon
Principal Investigator: Howard Hochster

Gastric and Esophageal

10
(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 4 - LGX818 for patients with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lung | Pancreas | Stomach
Principal Investigator: Joseph Paul Eder
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lip, Oral Cavity and Pharynx | Stomach
Principal Investigator: Lajos Pusztai
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients with Refractory Gastrointestinal Stromal Tumor
Disease/Condition: Cancer | Other Digestive Organ
Principal Investigator: Howard Hochster
A RANDOMIZED, MULTICENTER, ADAPTIVE PHASE II/III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS TAXANE (DOCETAXEL OR PACLITAXEL) IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION
Disease/Condition: Adenocarcinoma of the Gastroesophageal Junction | Esophagus | Gastric Cancer | Stomach
Principal Investigator: Howard Hochster
Phase 2 Single Arm, Two Cohort Study Evaluating AMG 337 in Subjects with MET Amplif. GI/GEJ/E cancer
Disease/Condition: Esophagus | Stomach
Principal Investigator: Howard Hochster
Phase 2 Study of Cabazitaxel in Refractory Metastatic Gastric and Gastroesophageal Adenocarcinoma
Disease/Condition: Esophagus | Other Digestive Organ
Principal Investigator: Jeremy Kortmansky
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Disease/Condition: Esophagus
Principal Investigator: Daniel Boffa

Liver Cancer

10
There are currently no trials available in this category.

Pancreatic Cancer

10
(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 4 - LGX818 for patients with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lung | Pancreas | Stomach
Principal Investigator: Joseph Paul Eder
A Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Disease/Condition: Pancreas
Principal Investigator: Stacey Stein
Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Disease/Condition: Pancreas
Principal Investigator: Jill Lacy